APA

Imai H., Kaira K., Mori K., Kotake M., Mitani M., Kawashima N., Hisada T. & Minato K. (20200810). Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors. : Thoracic cancer.

Chicago

Imai Hisao, Kaira Kyoichi, Mori Keita, Kotake Mie, Mitani Masumi, Kawashima Naoko, Hisada Takeshi and Minato Koichi. 20200810. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors. : Thoracic cancer.

Harvard

Imai H., Kaira K., Mori K., Kotake M., Mitani M., Kawashima N., Hisada T. and Minato K. (20200810). Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors. : Thoracic cancer.

MLA

Imai Hisao, Kaira Kyoichi, Mori Keita, Kotake Mie, Mitani Masumi, Kawashima Naoko, Hisada Takeshi and Minato Koichi. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors. : Thoracic cancer. 20200810.